Trial Profile

Conversion Effects of PD-1 Antibody Camrelizumab Combined With Nab-POF Regimen Chemotherpy in Patients With Initially Unresectable Locally Advanced or Limited Metastatic Gastric or Gastroesophageal Junction AdenocarcinomaFDZL-GC001 Trial

Status: Completed

Phase of Trial: Phase II

Latest Information Update: 14 Mar 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Camrelizumab (Primary) ; Fluorouracil (Primary) ; Folinic acid (Primary) ; Oxaliplatin (Primary) ; Paclitaxel (Primary) ; Trastuzumab (Primary)
Indications Adenocarcinoma; Gastric cancer; Liver metastases; Oesophageal cancer
Focus Therapeutic Use

12 Mar 2025 Status changed from recruiting to completed.
24 Oct 2023 Results (n=35) assessing conversion efficacy of camrelizumab with modified FLOT (mFLOT) regimen in patients(pts) with initially unresectable locally advanced or limited metastatic gastric or gastroesophageal junction (GEJ) adenocarcinoma were presented at the 48th European Society for Medical Oncology Congress.
13 Aug 2020 New trial record

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com